Citizens Business Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6,090
Closed -$4.71M 143
2026
Q1
$4.71M Sell
6,090
-92
-1% -$70.4K 0.77% 43
2025
Q4
$4.77M Buy
6,182
+63
+1% +$42.8K 0.79% 42
2025
Q3
$3.44M Sell
6,119
-6
-0.1% -$3.39K 0.57% 52
2025
Q2
$3.22M Buy
6,125
+114
+2% +$63.6K 0.62% 48
2025
Q1
$3.81M Buy
+6,011
New +$4.13M 0.83% 41

Other funds holding REGN

Citizens Business Bank's REGN Position: Q2 2026 in Review

Citizens Business Bank sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 6,090 shares — an estimated $4.71M sold.

Citizens Business Bank first reported a position in REGN in Q1 2025 and held it in 5 quarters. The position peaked at $4.77M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Citizens Business Bank reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citizens Business Bank sold 6,090 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.71M.
  • Citizens Business Bank first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Citizens Business Bank's Regeneron Pharmaceuticals position peaked at $4.77M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Citizens Business Bank's 13F filing for Q2 2026, filed 3 Aug 2026.